Meloxicam Tablet
Product Images NDC 72865-137

This is a description of a medication called Meloxicam Tablets USP. It comes in a bottle with 1000 tablets and is only available through prescription by a pharmacist. The medication guide must be included with each prescription. It should be stored in a dry, cool area, kept in a secure container, and should not be within reach of children. The manufacturer is Socent Pharmaceuticals, and it is produced for XLCare Pharmaceuticals. The address of XLCare Pharmaceuticals is 242 South Cuber Street, St 202, Lawrenceville, GA 30045.*

This is a medication label for the drug Eloxican, which should be stored between 20° to 25°C (68° to 77°F) and dispensed in a tight container. The medication should be kept in a dry place and out of reach of children. The label also includes the manufacturer's information, Rocot Phamaceutcl, and the manufacturer for XLCare Pharmaceuticals. Pharmacist should dispense the medication with an accompanying medication guide.*

XLcare Meloxicam Tablets USP, 75mg strength, is an RX-only medication available in a 1000 tablet count bottle. It is recommended to store the medication in a tightly sealed container at controlled room temperature and in a dry place. Patients are advised to read the accompanying prescribing information. The medication is manufactured by Ascent Pharmaceuticals and distributed by XLCare Pharmaceuticals. Pharmacists are advised to dispense the medication along with the accompanying medication guide and to keep all drugs out of reach of children.*

This text is a description of a medication, providing information on its storage requirements, dosage, and manufacturer. It also includes the NDC number, which is used for tracking purposes, and a warning to keep the medication out of reach of children. However, it does not identify the name or purpose of the medication, making it difficult to provide a comprehensive description.*

This document appears to be a list of potential side effects or symptoms that can occur during treatments for various ailments. It is not specific to any one treatment or disorder, but rather a general overview of possible health issues. It includes symptoms related to various body systems, such as cardiovascular, gastrointestinal, nervous, and urinary, as well as general symptoms, such as fatigue and weight changes. Many of the symptoms listed are serious and can be harmful, so it is important to seek medical attention if they occur.*

This is a table that shows the percentage of adverse events in 22% of patients who were administered meloxicam in a 12-week osteoarthritis trial. The table compares the effects of meloxicam, diclofenac, and placebo. The study included 157 patients on placebo, 154 on meloxicam 15mg, 156 on meloxicam 100mg and 153 on diclofenac. The table reports the percentage of patients who experienced side effects in various categories such as gastrointestinal, respiratory, body, nervous system, and skin. The table also indicates that meloxicam patients experienced better gastrointestinal tolerability in comparison to diclofenac.*

This is a table showing adverse events occurring in patients treated with meloxicam in two 12-week rheumatoid arthritis placebo-controlled trials. The table lists the adverse events that occurred in more than 2% of patients taking meloxicam in each dosage group compared to placebo. The common events observed were gastrointestinal disorders, dyspeptic signs and symptoms, nausea, joint-related signs and symptoms, headaches, and rash.*

This is a table showing the percentage of adverse events occurring in more than 2% of patients taking Meloxicam in controlled trials for osteoarthritis. The trials lasted 4 to 6 weeks and 6 months, and patients took a daily dose of either 75mg or 15mg. The adverse events include gastrointestinal issues such as abdominal pain, constipation, and nausea, as well as body pain, dizziness, headache, respiratory problems, and urinary tract infections. The table also shows the number of patients experiencing each adverse event for each dosage level.*

This text provides a pharmacokinetic comparison of single dose and steady-state oral Meloxicam (7.5 mg or 15mg) in healthy adults, elderly males and females, and individuals with renal or hepatic failure or insufficiency. The table shows the average pharmacokinetic parameters, including plasma concentration (Comx in gml), volume of distribution (Vi in L), systemic clearance (CLt in mUmin), and terminal phase half-life (tp in hours), between different formulations, such as tablets and capsules, and various dosages under high-fat and fasted conditions. However, the text is missing crucial information, and some parts are not readable, making it hard to determine the context.*